<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36899448</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis-a cross-sectional multicenter study.</ArticleTitle><Pagination><StartPage>1600</StartPage><EndPage>1610</EndPage><MedlinePgn>1600-1610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15773</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The objective was to assess the performance of serum neurofilament light chain (sNfL) in amyotrophic lateral sclerosis (ALS) in a wide range of disease courses, in terms of progression, duration and tracheostomy invasive ventilation (TIV).</AbstractText><AbstractText Label="METHODS">A prospective cross-sectional study at 12 ALS centers in Germany was performed. sNfL concentrations were age adjusted using sNfL Z scores expressing the number of standard deviations from the mean of a control reference database and correlated to ALS duration and ALS progression rate (ALS-PR), defined by the decline of the ALS Functional Rating Scale.</AbstractText><AbstractText Label="RESULTS">In the total ALS cohort (n&#xa0;=&#xa0;1378) the sNfL Z score was elevated (3.04; 2.46-3.43; 99.88th percentile). There was a strong correlation of sNfL Z score with ALS-PR (p&#x2009;&lt;&#x2009;0.001). In patients with long (5-10&#x2009;years, n&#xa0;=&#xa0;167) or very long ALS duration (&gt;10&#x2009;years, n&#xa0;=&#xa0;94) the sNfL Z score was significantly lower compared to the typical ALS duration of &lt;5&#x2009;years (n&#xa0;=&#xa0;1059) (p&#x2009;&lt;&#x2009;0.001). Furthermore, in patients with TIV, decreasing sNfL Z scores were found in correlation with TIV duration and ALS-PR (p&#xa0;=&#xa0;0.002; p&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">The finding of moderate sNfL elevation in patients with long ALS duration underlined the favorable prognosis of low sNfL. The strong correlation of sNfL Z score with ALS-PR strengthened its value as progression marker in clinical management and research. The lowering of sNfL in correlation with long TIV duration could reflect a reduction either in disease activity or in the neuroaxonal substrate of biomarker formation during the protracted course of ALS.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2736-7350</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APST Research GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salkic</LastName><ForeName>Erma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grehl</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Alfried Krupp Krankenhaus, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weyen</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Berufsgenossenschaftliches Universit&#xe4;tsklinikum Bergmannsheil, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettemann</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weydt</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Disorders and Gerontopsychiatry, Bonn University, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), Research Site Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0329-5644</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Dresden (DZNE), Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingor</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Jan Christoph</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsmedizin G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Translational Neurodegeneration Section "Albrecht-Kossel", University of Rostock, University Medical Center, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Rostock/Greifswald, DZNE, Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudlo</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Rostock/Greifswald, DZNE, Greifswald, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gro&#xdf;kreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsmedizin Schleswig-Holstein, Campus L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baum</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsklinikum Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boentert</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsklinikum M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metelmann</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universit&#xe4;tsklinikum Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norden</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordts</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2078-1997</Identifier><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division for Neurodegenerative Diseases, Department of Neurology, Mannheim Center for Translational Medicine, University Medicine Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6352-0909</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Ulm (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koc</LastName><ForeName>Yasemin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Bertram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APST Research GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spittel</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APST Research GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dreger</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rtv&#xe9;lyessy</LastName><ForeName>P&#xe9;ter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1262-6169</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Berlin Institute of Health, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Research Site Magdeburg (DZNE), Magdeburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">long disease duration</Keyword><Keyword MajorTopicYN="N">sNfL Z score</Keyword><Keyword MajorTopicYN="N">serum neurofilament light chain (sNfL)</Keyword><Keyword MajorTopicYN="N">tracheostomy invasive ventilation (TIV)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>23</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36899448</ArticleId><ArticleId IdType="doi">10.1111/ene.15773</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology. 2013;12:310-322.</Citation></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310-323.</Citation></Reference><Reference><Citation>Bianchi E, Pupillo E, de Feudis A, Enia G, Vitelli E, Beghi E. Trends in survival of ALS from a population-based registry. Amyotroph Lateral Scler Frontotemporal Degener. 2021;23:1-9.</Citation></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59-e69.</Citation></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22-e30.</Citation></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12-20.</Citation></Reference><Reference><Citation>Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:251-257.</Citation></Reference><Reference><Citation>Vacchiano V, Mastrangelo A, Zenesini C, et al. Plasma and CSF neurofilament light chain in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Front Aging Neurosci. 2021;13:753242.</Citation></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.</Citation></Reference><Reference><Citation>Behzadi A, Pujol-Calder&#xf3;n F, Tjust AE, et al. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep. 2021;11:22128.</Citation></Reference><Reference><Citation>Dreger M, Steinbach R, Gaur N, et al. Cerebrospinal fluid neurofilament light chain (NfL) predicts disease aggressiveness in amyotrophic lateral sclerosis: an application of the D50 disease progression model. Front Neurosci. 2021;15:651651.</Citation></Reference><Reference><Citation>Poesen K, de Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302-2309.</Citation></Reference><Reference><Citation>Zhang L, Ji T, Wu C, et al. Serum neurofilament light chain levels may be a marker of lower motor neuron damage in amyotrophic lateral sclerosis. Front Neurol. 2022;13:833507.</Citation></Reference><Reference><Citation>Thompson AG, Gray E, Verber N, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4:fcac029.</Citation></Reference><Reference><Citation>Verde F, Otto M, Silani V. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199.</Citation></Reference><Reference><Citation>Poesen K, van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2018;9:1167.</Citation></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109-119.</Citation></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099-1110.</Citation></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103-1116.</Citation></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157-164.</Citation></Reference><Reference><Citation>Steinacker P, Huss A, Mayer B, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:112-119.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453-1457.</Citation></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975-1978.</Citation></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647-653.</Citation></Reference><Reference><Citation>F&#xfc;rstenau D, Klein S, Vogel A, Auschra C. Multi-sided platform and data-driven care research. Electron Markets. 2021;31:811-828.</Citation></Reference><Reference><Citation>Meyer T, Kettemann D, Maier A, et al. Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. J Neurol Neurosurg Psychiatry. 2020;91:783-785.</Citation></Reference><Reference><Citation>Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11:812.</Citation></Reference><Reference><Citation>Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology. 2022;21:246-257.</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169:13-21.</Citation></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265-267.</Citation></Reference><Reference><Citation>Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265:510-521.</Citation></Reference><Reference><Citation>Hviid CVB, Knudsen CS, Parkner T. Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand J Clin Lab Invest. 2020;80:291-295.</Citation></Reference><Reference><Citation>Tortelli R, Copetti M, Ruggieri M, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol. 2015;22:215-218.</Citation></Reference><Reference><Citation>Steinacker P, Verde F, Fang L, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018;89:239-247.</Citation></Reference><Reference><Citation>Gong Z-Y, Lv G-P, Gao L-N, Lu Y, Guo J, Zang D-W. Neurofilament subunit L levels in the cerebrospinal fluid and serum of patients with amyotrophic lateral sclerosis. Neurodegener Dis. 2018;18:165-172.</Citation></Reference><Reference><Citation>Scarafino A, D'Errico E, Introna A, et al. Diagnostic and prognostic power of CSF tau in amyotrophic lateral sclerosis. J Neurol. 2018;265:2353-2362.</Citation></Reference><Reference><Citation>Spittel S, Maier A, Kettemann D, et al. Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: utilization and survival rates in a cohort study over 12&#x2009;years in Germany. Eur J Neurol. 2021;28:1160-1171.</Citation></Reference><Reference><Citation>Wicks P, Massagli MP, Wolf C, Heywood J. Measuring function in advanced ALS: validation of ALSFRS-EX extension items. Eur J Neurol. 2009;16:353-359.</Citation></Reference><Reference><Citation>Kettemann D, Funke A, Maier A, et al. Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:53-59.</Citation></Reference><Reference><Citation>Nishihira Y, Tan C-F, Toyoshima Y, et al. Sporadic amyotrophic lateral sclerosis: widespread multisystem degeneration with TDP-43 pathology in a patient after long-term survival on a respirator. Neuropathology. 2009;29:689-696.</Citation></Reference><Reference><Citation>Ito J, Shimada T, Tada M, et al. Clinicopathologic features of two patients with sporadic amyotrophic lateral sclerosis who maintained communication ability for over 30&#x2009;years. J Neuropathol Exp Neurol. 2018;77:981-986.</Citation></Reference><Reference><Citation>Mochizuki Y, Hayashi K, Nakayama Y, et al. ALS patients with ability to communicate after long-term mechanical ventilation have confined degeneration to the motor neuron system. J Neurol Sci. 2016;363:245-248.</Citation></Reference><Reference><Citation>Wurster CD, Steinacker P, G&#xfc;nther R, et al. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J Neurol. 2020;267:36-44.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>